Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Medical Therapies in Vitiligo
Description
The talk on medical therapies in vitiligo highlights the rapid advancements in treatment options over recent years and emphasizes the necessity for a comprehensive approach due to the complex nature of the disease. Unlike other autoimmune conditions, treating vitiligo requires inducing the proliferation and differentiation of melanocyte stem cells for repigmentation, thus combination therapies are recommended. Treatments may include narrowband UVB therapy combined with topical corticosteroids or immunomodulators, showing significant effects in over 80-90% of cases. New treatments such as topical ruxolitinib cream have shown promising results, particularly on the face, while newer systemic treatments like JAK inhibitors are being tested for widespread vitiligo. The importance of managing patient expectations is stressed since treatments require long-term commitment and there is a substantial risk of relapse. Studies indicate that combining therapies may lead to better outcomes, as ongoing and phase III studies are currently evaluating the efficacy of these approaches. Ultimately, while some progress is being made, patients must manage their treatment over extended periods to achieve optimal results.
View moreConclusions
- Combination approaches are essential for effective vitiligo treatment, requiring both a halt to depigmentation and inducing repigmentation.
- Optimal repigmentation in vitiligo can take 12 to 24 months, requiring patient education on the extended time frame for treatment effectiveness.
- More than 40% of patients may relapse within a year after achieving repigmentation, emphasizing the need for preventive strategies.
- Topical treatments like ruxolitinib and combination with narrowband UVB phototherapy show promising efficacy for both localized and extensive vitiligo.
- The efficacy of new oral JAK inhibitors shows encouraging results in active forms of vitiligo but requires further validation.
- Safety data indicates that topical ruxolitinib and oral JAK inhibitors generally have a good tolerance profile, with common but manageable side effects.
- Patients typically do not achieve complete repigmentation with monotherapy; hence, combination therapies may be necessary for achieving optimal results.
- Passeron T. Lancet. 2020;396(10244):74-75.
- van Geel N, et al. J Eur Acad Dermatol Venereol. 2023.
- Tovar-Garza A, et al. Br J Dermatol. 2019;180:193-194.
- Rosmarin D, et al. N Engl J Med. 2022;387:1445-1455.
- Wolkerstorfer A, et al. EADV 2022. Oral presentation FC01.04.
- Pandya AG, et al. J Invest Dermatol. 2022;142(12):3352-3355.
- Cavalié M, et al. Invest Dermato/ 2015;135:970-974.
- Van Geel N et al. Brit J Dermatol 2020.